IMV - IMV finalizes basket study in collaboration with Merck in bladder cancer solid tumors

IMV (NASDAQ:IMV) announces the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S) in combination with Merck’s Keytruda in patients with metastatic bladder and Micro-Satellite Instability High (MSI-H) solid tumors. Shares up 6.3% premarket at $1.36. “We are especially motivated by the responses observed in advanced, metastatic bladder cancer, where patients previously treated with an immune checkpoint inhibitor demonstrated clinical response, including complete responses,” commented Olivier Rixe, M.D., Ph.D., Director, Principal Investigator at Quantum Santa Fe in New Mexico, and Principal Investigator of the study. This Phase 2 basket trial is evaluating MVP-S across five cohorts of patients with bladder cancer, liver cancer, ovarian cancer, non-small cell lung cancer and tumors shown to be positive for the MSI-H biomarker. Subjects received MVP-S in combination with pembrolizumab and/or intermittent low dose cyclophosphamide. The study was designed to assess primary endpoints of safety and objective response rate, with multiple secondary and exploratory measures. IMV enrolled 131 patients

For further details see:

IMV finalizes basket study in collaboration with Merck in bladder cancer, solid tumors